Person: KIRPINAR, İSMET
12 results
Search Results
Now showing 1 - 10 of 12
Publication Open Access COVID-19 infection, vaccine status, and avoidance behaviors in adults with attention deficit and hyperactivity disorder: A cross-sectional study(2022-08-01) KILIÇ Ö.; BOYLU M. E.; Karakaya-Erdur S.; Suma-Berberoglu M.; Gudjonsson G.; Young S.; Deveci E.; KIRPINAR İ.; KILIÇ, ÖZGE; BOYLU, MUHAMMED EMİN; DEVECİ, ERDEM; KIRPINAR, İSMETObjective: We aim to examine infection risk and vaccine status of COVID-19 in attention deficit and hyperactivity disorder and evaluate the impact of demographic, clinical, and COVID-19-related factors on the infection status and behavioral avoidance of COVID-19. Methods: This cross-sectional study assessed adults with attention deficit and hyperactivity disorder recruited from an outpatient psychiatry clinic. Patients and healthy controls completed a survey on sociodemographic data, COVID-19 infection status, and vaccine status. COVID-19 Disease Perception Scale, COVID-19 Avoidance Attitudes Scale, Attitudes toward COVID-19 Vaccine Scale, Adult Attention Deficit and Hyperactivity Disorder Self-report Screening Scale for DSM-5, Adult Attention Deficit and Hyperactivity Disorder Self-Report Scale Symptoms Checklist, Patient Health Questionnaire-9, and State-Trait Anxiety Inventory were applied. Results: Ninety patients and 40 healthy controls participated. Patients did not differ from controls in COVID-19 infection and vaccine status, and behavioral avoidance of COVID-19. No demographic and clinical factor significantly affected the COVID-19 infection status. Patients scored higher than controls in the perception of COVID-19 as contagious (p = 0.038), cognitive avoidance of COVID-19 (p = 0.008), and positive attitudes toward the COVID-19 vaccine (p = 0.024). After adjustment of possible factors, a positive perception of the COVID-19 vaccine and a perception of COVID-19 as dangerous were the two factors significantly affecting behavioral avoidance of COVID-19 [R 2 = 0. 17, F(2) = 13.189, p < 0.0001]. Conclusion: Infection and vaccine status of COVID-19 in patients did not significantly differ from controls. No demographic and clinical factor significantly affected the COVID-19 infection status. Approximately four-fifths of the patients were fully vaccinated as recommended by national and global health organizations. This has increased the knowledge base showing that the COVID-19 vaccine is acceptable and receiving the vaccine is endorsed by ADHD patients. Attention deficit and hyperactivity disorder itself may provoke no kind of mental disturbance in sense of perception of the danger of this disease. Our findings have increased the knowledge base showing that the COVID-19 vaccine is acceptable and the actual practice of receiving the vaccine is endorsed in this population. Our message for practice would be to take into account not only the core symptoms and the comorbidities of the disorder but also the perception of the disease while exploring its link with COVID-19.Publication Open Access Clozapine Treatment and Thrombocytopenia: a Case Report(2014-09-01) Ozturk, AHMET; Deveci, ERDEM; DURSUN, Ali Emre; Soyucok, Etem; Kirpinar, Ismet; DEVECİ, ERDEM; KIRPINAR, İSMETPublication Open Access Development of Hyperprolactinemia Induced by the Addition of Bupropion to Venlafaxine XR Treatment(2018-04-01) KILIÇ, Alperen; Ozturk, AHMET; Deveci, ERDEM; Kirpinar, Ismet; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMETHyperprolactinemia is characterized by abnormally increased serum prolactin levels. Menstrual irregularities and hyperprolactinemia can be caused by a variety of medical conditions as well as due to the use of some psychopharmacological drugs, namely antipsychotics; it can also develop during antidepressant treatment. Bupropion is an antidepressant functioning via the inhibition of noradrenaline and dopamine reuptake. The endocrine and sexual adverse events of this agent are rare. In the literature, only one case reporting hyperprolactinemia or galactorrhea caused by bupropion use is available. Here, we present the case of a patient diagnosed with depressive disorder and receiving venlafaxine, who developed hyperprolactinemia and oligomenorrhea after the addition of bupropion the ongoing treatment and showed serum prolactin levels decreased to normal ranges shortly after the discontinuation of bupropion.Publication Open Access Assessing and Managing Delirium in Surgical and Internal Medicine: an Overview(2016-12-01) Kirpinar, Ismet; KIRPINAR, İSMETDelirium is most common neuropsychiatric disorder that affects patients in surgical and internal medicine clinics. It is defined as a transient, usually reversible organic mental disorder that has a rapid onset and fluctuating course. Clinically, delirium is an acute or subacute organic mental syndrome that is characterized by a disturbance in attention (reduced ability to direct, focus, sustain, and shift attention), awareness (reduced orientation to the environment), and other cognitive abilities (e.g., memory deficit and disorientation) and is not better explained by preexisting, established, or other evolving neurocognitive disorders. Studies have found that between 10% and 20% of all adult inpatients are diagnosed with delirium and that it occurs in up to 50% of elderly inpatients. Delirium itself is not a disease but rather a clinical syndrome, which results from an underlying disease. There is evidence from the history, physical examination, or laboratory findings that the disturbance is a physiological consequence of an underlying medical condition, substance intoxication or withdrawal, use of a medication, or a toxin exposure, or it is a combination of these factors. Accurate identification of underlying causes and risk factors is essential in early stage diagnosis and treatment. Treatment of delirium requires the treatment of the underlying causes. Psychotropic medications are used to comfort patients or enable better patient management. This study aims to review the clinical characteristics, etiological and risk factors, and different methods to obtain an accurate diagnosis and treatment of delirium.Publication Open Access COVID-19 Pandemic: Stress and Psychiatric Disorders(2021-02-01T00:00:00Z) KIRPINAR, İSMET; KIRPINAR, İSMETThe epidemic, which first started as viral pneumonia in Wuhan, China at the end of 2019 and is now known as Coronavirus disease-19 (COVID-19). rapidly spread to almost every part of the world and named a pandemic in March 2020. It is well known that psychiatric symptoms and syndromes, especially posttraumatic stress disorder, major depression, anxiety, and sleep disorders reach high prevalence values in natural or man-made disasters, Especially in infectious disease epidemics where mortality rates are high, patients, those who arc quarantined, and the whole society experience very intense mental stress and trauma. It is not easy to avoid psychological distress after facing highly fatal illnesses such as Ebola, severe acute respiratory syndrome (SARS), or COVID-19. When pandemics turn into a rapid and global disaster, the prevalence values of mental problems reach even higher levels. Combating mental disorders not only provides psychological well-being but also affects the course of the epidemic, as these disorders can delay efforts to fight epidemics. Mental health complaints increase in healthcare workers as a result of the stress and trauma of working during the epidemic. Studies report that during the SARS epidemic, approximately one-fifth of healthcare workers experienced 'significant mental disorders'. Medical professionals who develop mental disorders will be less productive, which will weaken the fight against the epidemic. Therefore, it is very important to support healthcare professionals. Since the COVID-19 outbreak is a relatively recent disaster, epidemiological study results have not yet been published sufficiently. However, the results of serious epidemics caused by viruses such as SARS and Ebola have previously been published. In this review, information about the psychiatric morbidity expected after COVID-19 is reviewed in the light of the results of studies conducted mainly in previous virus epidemics.Publication Open Access Can we predict who will be more anxious and depressed in the COVID-19 ward?(2021-01-01T00:00:00Z) Sahan, Ebru; Unal, Shafiga Mursalova; KIRPINAR, İSMET; ŞAHAN, EBRU; KIRPINAR, İSMETObjective: Hospitalized patients with COVID-19 are at high risk for anxiety and depression, but most studies about mental health during the pandemic included the general public, healthcare workers, and students. We aimed to explore the anxiety and depression levels, prevalence and predictors in patients hospitalized with COVID-19. Methods: In this cross-sectional, exploratory study, sociodemographic and clinical features of 281 patients with confirmed COVID-19 were explored. Patients underwent a comprehensive psychiatric assessment and the Hospital Anxiety and Depression Scale (HADS) was administered through a telephonic interview. Results: The mean age of the participants was 55.0 ± 14.9 years. One hundred forty-three (50.9%) patients were male, and 138 (49.1%) were female. Ninety-eight (34.9%) patients had significant levels of anxiety and 118 (42.0%) had significant levels of depression. Female gender, staying alone in a hospital room, early days of hospital stay, and any lifetime psychiatric disorder was associated with symptoms of anxiety. Being over 50 years of age, staying alone in a hospital room, and NSAID use before the week of hospital admission were associated with symptoms of depression. Anxiety and depression levels were lower when family members who tested positive for COVID-19 stayed in the same hospital room during treatment. Conclusion: Women, patients >50 years, patients who used NSAIDs before hospital admission, and those with lifetime psychiatric disorders may be at risk for anxiety and depressive symptoms in the COVID-19 ward. Allowing family members with COVID-19 to stay in the same hospital room may be associated with lower anxiety and depression levels.Publication Open Access Improvement in attention and executive functions during isotretinoin treatment in patients with acne(2013-06-01) Deveci, ERDEM; Ozturk, AHMET; Kirpinar, Ismet; ENGIN, Ragip Ismail; MELIKOGLU, Mehmet; SAKAT, Selcen Caferoglu; DEMIR, Muhammet; CANPOLAT, Serpil; DEVECİ, ERDEM; ÖZTÜRK, AHMET; KIRPINAR, İSMETBackground and Design: We assessed attention, memory, verbal-linguistic ability, and executive functions in acne vulgaris patients before and during isotretinoin treatment.Publication Open Access A Treatment-Response Comparison Study of Resting-State Functional Magnetic Resonance Imaging Between Standard Treatment of SSRI and Standard Treatment of SSRI Plus Non-dominant Hand-Writing Task in Patients With Major Depressive Disorder(2021-09-01T00:00:00Z) BOYRAZ, Rabia Kevser; KIRPINAR, İSMET; YILMAZ, Onur; Ozyurt, Onur; KILIÇARSLAN, TEZER; ARALAŞMAK, Ayşe; BOYRAZ, RABIA KEVSER; KIRPINAR, İSMET; YILMAZ, ONUR; KILIÇARSLAN, TEZER; ARALAŞMAK, AYŞEBackground: Researches have recently shifted from functional/structural imaging studies to functional connectivity (FC) studies in major depressive disorder (MDD). We aimed to compare treatment response of two treatment groups before and after treatment, in terms of both with psychiatric evaluation scales and resting-state functional connectivity (RSFC) changes in order to objectively demonstrate the possible contribution of the non-dominant hand-writing exercise (NHE) effect on depression treatment.Publication Open Access Investigation of facial emotion recognition, alexithymia, and levels of anxiety and depression in patients with somatic symptoms and related disorders(2016-04-29) ÖZTÜRK, AHMET; KILIÇ, Alperen; DEVECİ, ERDEM; KIRPINAR, İSMET; ÖZTÜRK, AHMET; DEVECİ, ERDEM; KIRPINAR, İSMETBackground: The concept of facial emotion recognition is well established in various neuropsychiatric disorders. Although emotional disturbances are strongly associated with somatoform disorders, there are a restricted number of studies that have investigated facial emotion recognition in somatoform disorders. Furthermore, there have been no studies that have regarded this issue using the new diagnostic criteria for somatoform disorders as somatic symptoms and related disorders (SSD). In this study, we aimed to compare the factors of facial emotion recognition between patients with SSD and age- and sex-matched healthy controls (HC) and to retest and investigate the factors of facial emotion recognition using the new criteria for SSD. Patients and methods: After applying the inclusion and exclusion criteria, 54 patients who were diagnosed with SSD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria and 46 age- and sex-matched HC were selected to participate in the present study. Facial emotion recognition, alexithymia, and the status of anxiety and depression were compared between the groups. Results: Patients with SSD had significantly decreased scores of facial emotion for fear faces, disgust faces, and neutral faces compared with age- and sex-matched HC (t=-2.88, P=0.005; t=-2.86, P=0.005; and t=-2.56, P=0.009, respectively). After eliminating the effects of alexithymia and depressive and anxious states, the groups were found to be similar in terms of their responses to facial emotion and mean reaction time to facial emotions. Discussion: Although there have been limited numbers of studies that have examined the recognition of facial emotion in patients with somatoform disorders, our study is the first to investigate facial recognition in patients with SSD diagnosed according to the DSM-5 criteria. Recognition of facial emotion was found to be disturbed in patients with SSD. However, our findings suggest that disturbances in facial recognition were significantly associated with alexithymia and the status of depression and anxiety, which is consistent with the previous studies. Further studies are needed to highlight the associations between facial emotion recognition and SSD.Publication Open Access Relationship of Asymmetrical Dimethylarginine, Nitric Oxide, and Sustained Attention during Attack in Patients with Major Depressive Disorder(2014-01-01) CANPOLAT, Serpil; Kirpinar, Ismet; Deveci, ERDEM; Aksoy, Hulya; BAYRAKTUTAN, Zafer; EREN, Ibrahim; Demir, Recep; Selek, Salih; Aydin, Nazan; KIRPINAR, İSMET; DEVECİ, ERDEMAbstract We investigated the relationship of serum nitric oxide (NO) and asymmetrical dimethylarginine (ADMA) levels with cognitive functioning in patients with major depressive disorder (MDD). 41 MDD patients (Beck depression scale scores>16) and 44 controls were included in the study. Rey verbal learning and memory test, auditory consonant trigram test, digit span test, Wisconsin card sorting test, continuous performance task (TOVA), and Stroop test scores were found to be impaired in patients with major depressive disorder when compared to healthy controls. There was no significant difference between patient and control groups in terms of serum NO and ADMA. Serum NO levels were correlated with TOVA test error scores and Stroop test time scores, whereas serum ADMA levels were negatively correlated with TOVA test error scores. Metabolic detriments especially in relation to NO metabolism in frontal cortex and hypothalamus, psychomotor retardation, or loss of motivation may explain these deficits.